Form 8-K - Current report:
SEC Accession No. 0000950170-22-012039
Filing Date
2022-06-23
Accepted
2022-06-23 16:31:13
Documents
13
Period of Report
2022-06-22
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20220622.htm   iXBRL 8-K 111169
2 EX-3.1 clsd-ex3_1.htm EX-3.1 21040
  Complete submission text file 0000950170-22-012039.txt   257489

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT clsd-20220622.xsd EX-101.SCH 2469
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT clsd-20220622_lab.xml EX-101.LAB 13897
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT clsd-20220622_pre.xml EX-101.PRE 10230
7 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20220622_htm.xml XML 4898
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 221035875
SIC: 2834 Pharmaceutical Preparations